登录后查看消息通知
搜索
常见问题
消息
登录
首页
/
数据集
/
TABLE 1 from Gemcitabine, Docetaxel, Capecitabine, Cisplatin, Irinotecan as First-line Treatment for Metastatic Pancreatic Cancer
TABLE 1 from Gemcitabine, Docetaxel, Capecitabine, Cisplatin, Irinotecan as First-line Treatment for Metastatic Pancreatic Cancer
收藏
Figshare
2023-08-28 更新
2026-04-28 收录
胰腺癌治疗
临床试验基线特征
数据链接：
https://figshare.com/articles/dataset/TABLE_1_from_Gemcitabine_Docetaxel_Capecitabine_Cisplatin_Irinotecan_as_First-line_Treatment_for_Metastatic_Pancreatic_Cancer/24043004
数据链接
链接失效反馈
官方服务：
问题咨询
购买咨询
在线客服
NEW
资源简介：
Baseline characteristics
应用场景：
创建时间：
2023-08-28
相关数据集
Demographic and baseline characteristics (ITT set).
临床试验基线特征
意向治疗分析
Demographic and baseline characteristics (ITT set).
NIAID Data Ecosystem
9
0
Baseline characteristics of the total ALL-IN study population and intervention and control group separately.
临床试验基线特征
Baseline characteristics of the total ALL-IN study population and intervention and control group separately.
NIAID Data Ecosystem
5
0
Baseline characteristics of randomised groups.
临床试验基线特征
Baseline characteristics of randomised groups.
NIAID Data Ecosystem
5
0
Supplementary Material for: Sustained clinical response to Olaparib in a patient with metastatic pancreatic cancer and somatic ATM-Mutation R2034Ter: a case report
胰腺癌治疗
PARP1抑制剂治疗
Background Pancreatic cancer remains a lethal disease with limited therapeutic options. The field of targeted therapies is still growing. Treatment with PARP inhibitors has been successfully described
DataCite Commons
2025-06-01 更新
8
0
Baseline demographic and clinical values at randomisation according to study group.
临床试验基线特征
随机对照试验
Baseline demographic and clinical values at randomisation according to study group.
NIAID Data Ecosystem
5
0
© 2023-2026 上海数据发展科技有限责任公司 版权所有
沪ICP备17003045号-15
沪公网安备31010402336585号
热门搜索
社区交流群
科研交流群
商业服务
数据资源
寻源服务
数据采集
标注服务
数据产品
代理销售
数据领域
凭证登记
数据产品
介绍推广
